# US 2022/0031692 A1 · Buprenorphine dosing regimens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031692 A1
- Document ID: US20220031692A1
- Status: Published application
- Kind: A1
- Application number: 17/217,914
- Filed: 2021-03-30
- Published: 2022-02-03
- Earliest claimed: 2014-11-07
- Assignees: Indivior UK Limited
- Applicants: Indivior UK Limited
- Inventors: Azmi NASSER; Celine M. LAFFONT; Christian A. HEIDBREDER
- Web page: https://patentgrep.com/patent/US20220031692A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/36: Opioid-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

## Claims

### Claim at position 1

1-67. (canceled)

### Claim 68

A method of treating opioid use disorder in a human in need thereof, the method comprising the steps of:
(a) administering a first composition comprising about 280 mg to 320 mg of buprenorphine to the human once per month by subcutaneous injection for two months; wherein the first composition comprises (i) about 18 wt % of buprenorphine free base; (ii) about 32 wt % of a poly(DL-lactide-co-glycolide) copolymer; and (iii) about 50 wt % of N-methyl-2-pyrrolidone; and
(b) administering a second composition comprising about 80 mg to 120 mg of buprenorphine to the human once per month by subcutaneous injection beginning with a third month; wherein the second composition comprises (i) about 18 wt % of buprenorphine free base; (ii) about 32 wt % of a poly(DL-lactide-co-glycolide) copolymer; and (iii) about 50 wt % of N-methyl-2-pyrrolidone; to treat the opioid use disorder.

### Claim 69 (depends on 68)

The method of claim 68, wherein the opioid use disorder is moderate opioid use disorder or severe opioid use disorder.

### Claim 70 (depends on 68)

The method of claim 68, wherein the poly(DL-lactide-co-glycolide) copolymer in the first composition and the second composition is a 50:50 poly(DL-lactide-co-glycolide) copolymer.

### Claim 71

A method of treating opioid use disorder in a human in need thereof, the method comprising the steps of:
(a) administering a first composition comprising about 280 mg to 320 mg of buprenorphine or a pharmaceutically acceptable salt thereof to the human once per month by injection for two months; and
(b) administering a second composition comprising about 80 mg to 120 mg of buprenorphine or a pharmaceutically acceptable salt thereof to the human once per month by injection beginning with a third month; to treat the opioid use disorder.

### Claim 72 (depends on 71)

The method of claim 71, wherein the buprenorphine is in the form of a free base.

### Claim 73 (depends on 71)

The method of claim 71, wherein the method produces an average buprenorphine plasma concentration of at least 2 ng/mL.

### Claim 74 (depends on 71)

The method of claim 71, wherein the method produces an average buprenorphine plasma concentration of about 2 ng/mL to about 5 ng/mL.

### Claim 75 (depends on 71)

The method of claim 71, wherein the method produces a μ-opioid receptor occupancy as measured by a maximum effect model of Equation 1 of at least 70%.

### Claim 76 (depends on 71)

The method of claim 71, wherein the injection is a subcutaneous injection.

### Claim 77 (depends on 71)

The method of claim 71, wherein the method of treating opioid use disorder is a method of suppressing opioid withdrawal signs and symptoms.

### Claim 78 (depends on 71)

The method of claim 71, wherein the first composition and the second composition each comprise:
(i) about 18 wt % of buprenorphine free base;
(ii) about 32 wt % of a 50:50 poly(DL-lactide-co-glycolide) copolymer; and
(iii) about 50 wt % of N-methyl-2-pyrrolidone.

### Claim 79 (depends on 71)

The method of claim 71, wherein the first composition and the second composition each comprise:
(i) about 14 wt % to about 22 wt % of buprenorphine free base;
(ii) about 22 wt % to about 42 wt % of a 50:50 to 80:20 poly(DL-lactide-co-glycolide) copolymer; and
(iii) about 40 wt % to about 60 wt % of N-methyl-2-pyrrolidone.

### Claim 80 (depends on 71)

The method of claim 71, wherein the first composition and the second composition each comprise:
(i) about 10 wt % to about 30 wt % of buprenorphine free base;
(ii) about 10 wt % to about 60 wt % of a 50:50 to 95:5 poly(DL-lactide-co-glycolide) copolymer; and
(iii) about 30 wt % to about 70 wt % of N-methyl-2-pyrrolidone.

### Claim 81 (depends on 68)

The method of claim 68, wherein the poly(DL-lactide-co-glycolide) copolymer in the first composition and the second composition is a 50:50 poly(DL-lactide-co-glycolide) copolymer having a carboxy terminal group and having an average molecular weight of about 9,000 Daltons to about 19,000 Daltons.

### Claim 82 (depends on 78)

The method of claim 78, wherein the 50:50 poly(DL-lactide-co-glycolide) copolymer has a carboxy terminal group and has an average molecular weight of about 9,000 Daltons to about 19,000 Daltons.

### Claim 83 (depends on 79)

The method of claim 79, wherein the 50:50 to 80:20 poly(DL-lactide-co glycolide) copolymer is a 50:50 to 80:20 poly(DL-lactide-co-glycolide) copolymer having an average molecular weight of about 5,000 Daltons to about 30,000 Daltons.

### Claim 84 (depends on 80)

The method of claim 80, wherein the 50:50 to 95:5 poly(DL-lactide-co-glycolide) copolymer is a 50:50 to 95:5 poly(DL-lactide-co-glycolide) copolymer having an average molecular weight of about 5,000 Daltons to about 40,000 Daltons.

### Claim 85 (depends on 71)

The method of claim 71, wherein the opioid use disorder is moderate opioid use disorder or severe opioid use disorder.

### Claim 86 (depends on 68)

The method of claim 68, further comprising transmucosally administering to the patient a composition comprising buprenorphine prior to step (a).

### Claim 87 (depends on 68)

The method of claim 68, further comprising sublingually administering to the patient a composition comprising buprenorphine prior to step (a).

### Claim 88 (depends on 68)

The method of claim 68, further comprising inducting and stabilizing the patient on a transmucosal composition comprising buprenorphine prior to step (a).

### Claim 89 (depends on 68)

The method of claim 68, further comprising inducting and stabilizing the patient on a sublingual composition comprising buprenorphine prior to step (a).

### Claim 90

A method of treating opioid addiction in a human in need thereof, the method comprising the steps of:
(a) transmucosally administering a composition comprising buprenorphine;
(b) subcutaneously administering a first composition comprising about 280 mg to 320 mg of buprenorphine once per month for two months; wherein the first composition comprises (i) about 18 wt % of buprenorphine free base; (ii) about 32 wt % of a poly(DL-lactide-co-glycolide) copolymer; and (iii) about 50 wt % of N-methyl-2-pyrrolidone; and
(c) subcutaneously administering a second composition comprising about 80 mg to 120 mg of buprenorphine once per month beginning with a third month; wherein the second composition comprises (i) about 18 wt % of buprenorphine free base; (ii) about 32 wt % of a poly(DL-lactide-co-glycolide) copolymer; and (iii) about 50 wt % of N-methyl-2-pyrrolidone.
